Results 181 to 190 of about 54,075 (219)

Poziotinib/trastuzumab-deruxtecan/trastuzumab-emtansine

Reactions Weekly, 2022
openaire   +1 more source

Pertuzumab/trastuzumab/trastuzumab-emtansine

Reactions Weekly, 2020
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2022
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2023
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2020
  +4 more sources

Trastuzumab

Reactions Weekly, 2021
openaire   +2 more sources

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

New England Journal of Medicine, 2022
Javier Cortes, Martina Uttenreuther-Fischer, Wei-Pang Chung   +2 more
exaly  

Trastuzumab/trastuzumab emtansine

Reactions Weekly, 2017
openaire   +1 more source

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Lancet, The, 2023
Akihito Kawazoe, Jian-Ming Xu, Sara Lonardi   +2 more
exaly  

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Lancet, The, 2010
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova   +2 more
exaly